Overall Survival Date From CodeBreaK 300 for KRAS G12C-Mutated mCRC

Filippo Pietrantonio, MD, of IRCCS Istituto Nazionale dei Tumori, and Nataliya Uboha, MD, PhD, of University of Wisconsin School of Medicine and Public Health, continue their conversation with a review of the overall survival data from the phase 3 CodeBreaK 300 study.
This trial investigated sotorasib plus panitumumab versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer.

[@user-ug9hd9nm5m]

Hi Dear.. I visited your RUclips channel and found it needs a lot of updates. First of all your channel video SEO is very weak due to which your channel video views are not increasing. If you do SEO then your video will come first in the search list and your video views and subscribers will increase. Do you want to customize your channel?